Clinical Trial Update: A Study to Understand the Safety of the 20vPnC Vaccine in Healthy Chinese Adults, Children, and Infant [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the safety of the 20-valent pneumococcal conjugate vaccine in healthy Chinese adults, children, and infants.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Disease

Drugs mentioned

• Prevnar 20 (20-valent pneumococcal conjugate vaccine)

Snippet

Sponsor: Pfizer | Conditions: Pneumococcal Disease | Phase 1 | Status: ACTIVE_NOT_RECRUITING